GRTSQ — Gritstone bio Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$15.21m
- $16.34m
Gritstone bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Gritstone Bio Reports First Quarter 2023 Financial Results And Provides Corporate Updates
Gritstone bio Inc expected to post a loss of 33 cents a share - Earnings Preview
Gritstone bio Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Gritstone Bio Presents Advances In Neoantigen Prediction And Cancer Vaccine Immunogenicity
Brief: Gritstone Bio Presents 6-Month Neutralizing Antibody (NAB) Data From Two Phase 1 Studies Evaluating Self-Amplifying Mrna (Samrna) Against Sars-Cov-2 (Coral)
Brief: Gritstone Bio Inc Currently Holds Balance Of Less Than $0.5 Mln In Cash With Silicon Valley Bank
Gritstone bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Gritstone Bio Reports Fourth Quarter And Full Year 2022 Financial Results
Gritstone bio Inc expected to post a loss of 34 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Packaged food makers, energy firms, Thomson Reuters
U.S. STOCKS ON THE MOVE-Ford Motor, Cleveland-Cliffs, Exelon Corp
U.S. STOCKS ON THE MOVE-Nvidia, Peabody Energy, Zoetis
Gritstone bio rises on clinical trial agreement with National Cancer Institute
Brief: Gritstone Bio And The National Cancer Institute (Nci) Establish A Clinical Trial Agreement To Evaluate A Neoantigen Cell Therapy-Vaccine Combination
Gritstone jumps on Moderna's cancer vaccine success, new patents
Gritstone bio jumps on patents for mRNA vaccine platform technology
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44% (updated)
Brief: Gritstone Bio Granted Two New U.S. Patents For SAMRNA